Table 1.
Intrathecal treatments using trastuzumab, alone or in association with other agents.
| Reference | Symptoms | WBRT | CSF before ITT | MRI | Intrathecal therapy | CSF after ITT | MRI | Clinical response | Toxicity | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| before ITT | Proteins | Malignant C | before ITT | Proteins | Malignant C | after ITT | |||||
| Stemmler et al., 2006[3] |
♀ 39 Y Headache, dizziness |
+ | Increased | + | No data | MTX 6 × 15 mg + Ommaya TST 5 mg, 10 mg, 15 mg, 20 mg, 20 mg |
Low | − | No data | Improved | None |
|
| |||||||||||
| Platini et al., 2006 [4] |
♀ 36 Y Vertigo, amnesia, mental confusion |
− | Increased | + | No data | MTX Peridural PAC 46 × 25 mg TST (17 mo) THI |
Normal | − | No data | Stable | None |
|
| |||||||||||
|
Colozzaet al., 2009 [5] |
♀ 38 Y Headache, dizziness, gait disorder |
+ | No lumbar punction | LMC+ | Ommaya 23 × 12.5 mg/3 weeks TST |
No data | − | Stable | Improved | None | |
|
| |||||||||||
| Ferrario et al., 2009 [6] |
♀ 31 Y Visual impairment, right ptosis, paralysis of the right facial nerve, and left foot drop |
− | Normal | + | No data | Ommaya TST 2 × 20 mg, 2 × 25 mg, 3 × 30 mg, TST 40 mg q3w × 8 mo TST 40 mg q3w + thiotepa 10 mg × 6 mo TST 50 mg q3W + 12 mg THI × 13 mo |
No data | − | Improvement | Complete recovery | None |
|
| |||||||||||
|
Mego et al., 2011 [7] |
♀ 43 Y Dizziness, cranial nerves palsy. |
+ | Increased | − | LMC+ | MTX 15 mg + CYT 24 mg + HDC 24 mg + 3 × 20 mg TST, 3 × 40 mg TST | Increased | − | No data | Improved | None |
| ♀ 39 Y Headache, dizziness, cranial nerve palsies, vision disorders |
+ | Increased | + | LMC+ | MTX 15 mg + CYT 24 mg + HDC 24 mg + TST 1 × 20 mg, 1 × 40 mg, 1 × 80 mg, 3 × 100 mg | No data | − | Improved | None | ||
|
| |||||||||||
| Oliveira et al., 2011 [8] |
♀ 40 Y Headache, vomiting, gait disturbance |
+ | No lumbar punction | LMC+ (CT scan exam) |
TST 25 mg + PRD 25 mg × 25 doses (2 years) | No data | Partial response | Complete recovery | None | ||
TST: trastuzumab, MTX: methotrexate, THI: thiotepa, HDC: hydrocortisone, PRD: prednisolone, CYT: cytarabine, MRI: magnetic resonance imaging, CSF: cerebrospinal fluid, mo: months, CT: computed tomography, WBRT: whole brain radiotherapy, ITT: intrathecal treatment, “+”: presence, “−”: absence, malignant C: malignant cells.